Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.
Saved in:
| Title: | Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial. |
|---|---|
| Authors: | Abdel Jawad M; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.; University of Missouri-Kansas City, Kansas City, MO, USA., Furtado RHM; Brazilian Clinical Research Institute, Sao Paulo, Brazil., Esterline R; Late-Stage Development, CVRM, AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, MD, USA., Oscarsson J; Late-Stage Development, CVRM, AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden., Gasparyan SB; Late-Stage Development, CVRM, AstraZeneca, BioPharmaceuticals R&D, Boston, MA, USA., Koch GG; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Martinez F; National University of Cordoba, Avenida Colon 2057, Córdoba, Argentina., Mukhtar O; Experimental Medicine & Immunotherapeutics Division, Department of Medicine, University of Cambridge, Cambridge, UK., Verma S; Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada.; Department of Surgery, University of Toronto, Toronto, ON, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada., Langkilde AM; Late-Stage Development, CVRM, AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden., Ambery P; Late-Stage Development, CVRM, AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden., Patel S; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.; University of Missouri-Kansas City, Kansas City, MO, USA., Gosch K; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.; University of Missouri-Kansas City, Kansas City, MO, USA., Windsor SL; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Soares RVP; Academic Research Organization- Einstein Hospital Israelita, Av. Albert Einstein 627, Sao Paulo-SP, Brazil., Moia DDF; Academic Research Organization- Einstein Hospital Israelita, Av. Albert Einstein 627, Sao Paulo-SP, Brazil., Aboudara M; Division of Pulmonary and Critical Care, Saint Luke's Health System, Kansas City, MO, USA., Javaheri A; Washington University School of Medicine and John Cochran VA Hospital, St. Louis, MO, USA., Saraiva JFK; Instituto de Pesquisa Clinica de Campinas, Campinas, Brazil., Maia LN; Centro Integrado de Pesquisas (CIP), Hospital de Base, Sao Jose Do Rio Preto, Brazil., Berwanger O; Imperial College London, London, UK.; George Institute for Global Health UK, London, UK., Sauer AJ; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA. asauer@saint-lukes.org.; University of Missouri-Kansas City, Kansas City, MO, USA. asauer@saint-lukes.org., Kosiborod MN; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.; University of Missouri-Kansas City, Kansas City, MO, USA.; Late-Stage Development, CVRM, AstraZeneca, BioPharmaceuticals R&D, Boston, MA, USA. |
| Source: | Cardiovascular diabetology [Cardiovasc Diabetol] 2025 Jul 30; Vol. 24 (1), pp. 307. Date of Electronic Publication: 2025 Jul 30. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1475-2840 |
|---|---|
| DOI: | 10.1186/s12933-025-02875-6 |
